Recombinant CD52 (Alemtuzumab Biosimilar) antibody

Catalog No. ABIN7795101

The Mouse Monoclonal anti-CD52 (Alemtuzumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect CD52 (Alemtuzumab Biosimilar) in samples from Human.

Quick Overview for Recombinant CD52 (Alemtuzumab Biosimilar) antibody (ABIN7795101)

Target: CD52 (Alemtuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD52 (Alemtuzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD52 (Alemtuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Alemtuzumab Biosimilar, Human CD52 Monoclonal Antibody

Characteristics: Alemtuzumab Biosimilar uses the same protein sequences as the therapeutic antibody alemtuzumab. Alemtuzumab is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein. It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD52

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD52 (Alemtuzumab Biosimilar)

Target: CD52 (Alemtuzumab Biosimilar)

Alternative Name: Alemtuzumab Biosimilar

Target Type: Biosimilar